A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Receptors, Estrogen|Genes, Erbb-2|Breast Neoplasms
Interventions: DRUG: Palbociclib (75, 100, 125 milligram [mg])|DRUG: H3B-6545 (150, 300, 450 mg)
Sponsor: Eisai Inc.